Table 2. Univariate analyses for survival outcomes.
| Variable | LRRFS | RFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | |
| Age ( < 50 yr vs. ≥ 50 yr) | 0.570 | 1.411 | 0.430–4.628 | 0.785 | 0.919 | 0.504–1.679 | 0.472 | 0.724 | 0.300–1.747 |
| MRI (none vs. done) | 0.938 | 1.055 | 0.270–4.124 | 0.508 | 0.775 | 0.364–1.650 | 0.655 | 0.791 | 0.283–2.213 |
| Tumor size (T1 vs. T2) | 0.053 | 3.223 | 0.983–10.564 | 0.000 | 3.358 | 1.844–6.115 | 0.019 | 2.821 | 1.188–6.695 |
| Nodal status (negative vs. positive) | 0.307 | 0.035 | 0.000–21.727 | 0.789 | 1.106 | 0.529–2.311 | 0.897 | 0.931 | 0.312–2.772 |
| Histologic type (ductal vs. other) | 0.481 | 1.317 | 0.612–2.836 | 0.321 | 1.228 | 0.819–1.841 | 0.810 | 0.914 | 0.441–1.896 |
| Histologic grade (I, II vs. III) | 0.231 | 1.495 | 0.775–2.886 | 0.016 | 1.499 | 1.079–2.082 | 0.010 | 1.915 | 1.168–3.140 |
| ER (negative vs. positive) | 0.822 | 0.869 | 0.254–2.968 | 0.015 | 0.475 | 0.261–0.864 | 0.010 | 0.312 | 0.129–0.754 |
| PR (negative vs. positive) | 0.721 | 0.806 | 0.246–2.642 | 0.010 | 0.445 | 0.242–0.821 | 0.047 | 0.410 | 0.170–0.989 |
| Hormonal therapy (none vs. done) | 0.100 | 0.369 | 0.112–1.209 | 0.006 | 0.426 | 0.232–0.781 | 0.014 | 0.343 | 0.145–0.807 |
| Adjuvant chemotherapy (none vs. done) | 0.957 | 0.968 | 0.295–3.172 | 0.031 | 2.082 | 1.069–4.055 | 0.314 | 1.594 | 0.643–3.949 |
LRRFS=locoregional recurrence-free survival; RFS=recurrence-free survival; OS=overall survival; HR=hazard ratio; CI=confidence interval; MRI=magnetic resonance imaging; ER=estrogen receptor; PR=progesterone receptor.